G
Gabriela Moeslein
Researcher at University of Düsseldorf
Publications - 38
Citations - 3437
Gabriela Moeslein is an academic researcher from University of Düsseldorf. The author has contributed to research in topics: Lynch syndrome & Colorectal cancer. The author has an hindex of 21, co-authored 37 publications receiving 3043 citations.
Papers
More filters
Journal ArticleDOI
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
John Burn,Anne-Marie Gerdes,Finlay A. Macrae,Jukka-Pekka Mecklin,Gabriela Moeslein,Sylviane Olschwang,D. Eccles,D. Gareth Evans,Eamonn R. Maher,Lucio Bertario,Marie Luise Bisgaard,Malcolm G. Dunlop,Judy W. C. Ho,Shirley V. Hodgson,Annika Lindblom,Jan Lubinski,Patrick J. Morrison,Victoria Murday,Raj Ramesar,Lucy Side,Rodney J. Scott,Huw Thomas,Hans F. A. Vasen,Gail Barker,Gillian Crawford,Faye Elliott,Mohammad Movahedi,Kirsi Pylvänäinen,Juul T. Wijnen,Riccardo Fodde,Henry T. Lynch,John C. Mathers,D. Timothy Bishop +32 more
TL;DR: The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer, and long-term follow-up of participants randomly assigned to aspirin or placebo is reported.
Journal ArticleDOI
Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database
Pål Møller,Toni T. Seppälä,Inge Bernstein,Inge Bernstein,Elke Holinski-Feder,Paulo Sala,D. Gareth Evans,D. Gareth Evans,Annika Lindblom,Finlay A. Macrae,Finlay A. Macrae,Ignacio Blanco,Rolf H. Sijmons,Jacqueline Jeffries,Hans F. A. Vasen,John Burn,Sigve Nakken,Eivind Hovig,Einar Andreas Rødland,Kukatharmini Tharmaratnam,Wouter H. de Vos tot Nederveen Cappel,James Hill,Juul T. Wijnen,Mark A. Jenkins,Kate Green,Kate Green,Fiona Lalloo,Fiona Lalloo,Lone Sunde,Miriam Mints,Lucio Bertario,Marta Pineda,Matilde Navarro,Monika Morak,Laura Renkonen-Sinisalo,Laura Renkonen-Sinisalo,Mev Dominguez Valentin,Ian M. Frayling,John-Paul Plazzer,Kirsi Pylvänäinen,Maurizio Genuardi,Jukka-Pekka Mecklin,Gabriela Moeslein,Julian R. Sampson,Gabriel Capellá +44 more
TL;DR: Carriers of different path_MMR variants exhibit distinct patterns of cancer risk and survival as they age, and risk estimates for counselling and planning of surveillance and treatment should be tailored to each patient’s age, gender and path-MMR variant.
Journal ArticleDOI
High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumors
TL;DR: In the current study, high doses of tamoxifen in combination with sulindac were used to treat severe desmoid tumors to avoid surgery.
Journal ArticleDOI
Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome
Christoph Engel,Markus Loeffler,Verena Steinke,Nils Rahner,Elke Holinski-Feder,Wolfgang Dietmaier,Hans K. Schackert,Heike Goergens,Magnus von Knebel Doeberitz,Timm O. Goecke,Wolff Schmiegel,Reinhard Buettner,Gabriela Moeslein,Tom G.W. Letteboer,Encarna B. Gomez Garcia,Frederik J. Hes,Nicoline Hoogerbrugge,Fred H. Menko,Theo A. M. van Os,Rolf H. Sijmons,Anja Wagner,Irma Kluijt,Peter Propping,Hans F. A. Vasen +23 more
TL;DR: The sex- and gene-specific differences of less common cancer risks should be taken into account in cancer surveillance and prevention programs for patients with Lynch syndrome.
Journal ArticleDOI
Lower Incidence of Colorectal Cancer and Later Age of Disease Onset in 27 Families With Pathogenic MSH6 Germline Mutations Compared With Families With MLH1 or MSH2 Mutations: The German Hereditary Nonpolyposis Colorectal Cancer Consortium
Jens Plaschke,Christoph Engel,Stefan Krüger,Elke Holinski-Feder,Constanze Pagenstecher,Elisabeth Mangold,Gabriela Moeslein,Karsten Schulmann,Johannes Gebert,Magnus von Knebel Doeberitz,Josef Rüschoff,Markus Loeffler,Hans K. Schackert +12 more
TL;DR: Later age of disease onset and lower incidence of colorectal cancer may contribute to a lower proportion of identified MSH6 mutations in families suspected of HNPCC, but a surveillance program as stringent as that for families with MLH1 or MSH2 mutations is recommended.